Insider Cluster (2 insiders) ·Filed Aug 19, 2026

TAK

TAKEDA PHARMACEUTICAL CO LTD
NEUTRAL
Impact 2/10
Horizonimmediate Processed1mo ago
Insider cluster: 2 insiders, $592K total
Actionable Insight • Neutral

This cluster is noise. The $592K in sales is trivial for a $57B company and likely reflects routine diversification or tax planning. No trading signal. Monitor for any material insider buying (which would be a stronger signal) or a change in the pattern of sales, but this filing alone warrants no action.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
TAK ▲ +3.87% at T+20d
NEUTRAL call ✓ call won +3.87% · α vs SPY +5.82% · entry $18.34 → $19.05
Next anchor: T+60d in 6w
Latest observation: T+28 -0.97% FF3 residual α
Entry anchored
Aug 18, 05:53 PM ET
via 1-min bar
T+1d
-1.15%
call -1.15% · α -0.31%
$18.13
settled 6w ago
T+5d
-0.60%
call -0.60% · α -0.21%
$18.23
settled 5w ago
T+20d
+3.87%
call +3.87% · α +5.82%
$19.05
settled 16d ago
T+60d
—
call — · α —
—
in 6w

Price Chart

Loading chart...

Executive Summary

Two Takeda insiders — the President of Global Supply & Quality and the Chief Human Resources Officer — sold a combined $592K in open-market sales over an 8-day window. The total value is ~0.001% of Takeda's $57B market cap, making this a trivial, routine cluster with no material signal. The sales are likely liquidity-driven (vesting/blackout window) and do not indicate a bearish view on the company's fundamentals, especially given the strong analyst consensus (67% bullish) and the company's large cap.

Key Financial Metrics

Direction
selling
Total Value
$592.0K
Insiders
2

Key Facts

  • Two insiders sold a total of ~33,400 shares for ~$592K in open-market transactions between Aug 11 and Aug 18, 2026.
  • The total sale value is approximately 0.001% of Takeda's $57B market cap, well below the 0.1% threshold for materiality.
  • Both sellers are senior executives (President of Global Supply & Quality and Chief Human Resources Officer), but the dollar amounts are immaterial.
  • No insider buying was detected in the cluster; the net direction is selling, but the scale is trivial.
  • The 30-day trailing insider activity shows $6.8M in total sales, consistent with routine portfolio management at a mega-cap pharma.

Financial Impact

Total insider sales of ~$592K, representing ~0.001% of market cap — immaterial.

insider_sales

Risk Factors

  • Insider sales could accelerate if management sees headwinds, but current volume is too small to indicate anything.
  • No risk from this filing — the cluster is immaterial in size.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (21 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-TAK-1787196903890
13 reports for TAK
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for TAK — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
6-K
BULLISH ★ 7/10
$18.60 $18.89▲ +1.56%▲ +1.45%$17.86 (−3.98%)
Aug 21, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$18.18 $18.03▼ −0.83%▼ −1.30%$17.86 (−1.76%)
Aug 19, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$18.34 $18.23▼ −0.60%▼ −0.21%$17.86 (−2.62%)
Aug 14, 2026
7w ago
Court Ruling
NEUTRAL ★ 4/10
$17.63 $18.18▲ +3.12%▲ +4.49%$17.86 (+1.30%)
Aug 13, 2026
7w ago
Insider Cluster
NEUTRAL ★ 3/10
$17.39 $18.13▲ +4.26%▲ +6.22%$17.86 (+2.70%)
Aug 13, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$17.39 $18.13▲ +4.26%▲ +6.22%$17.86 (+2.70%)
Jul 9, 2026
12w ago
6-K
NEUTRAL ★ 2/10
$16.61 $16.73▲ +0.72%▲ +0.85%$17.86 (+7.53%)
Jul 8, 2026
12w ago
6-K
NEUTRAL ★ 2/10
$16.75 $16.39▼ −2.15%▼ −3.01%$17.86 (+6.63%)
Jul 6, 2026
12w ago
3
NEUTRAL ★ 2/10
$16.89 $16.56▼ −1.95%▼ −2.44%$17.86 (+5.74%)
Jun 29, 2026
13w ago
6-K
NEUTRAL ★ 2/10
$15.98 $16.89▲ +5.69%▲ +4.31%$17.86 (+11.76%)
Showing 10 of 13

US Market Status

Market Closed — Opens Mon (65h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Aug 20, 2026